Literature DB >> 31194976

Gab2 promotes cancer stem cell like properties and metastatic growth of ovarian cancer via downregulation of miR-200c.

Zenghui Fang1, Tong Li1, Wanzhou Chen1, Du Wu1, Yaqian Qin1, Min Liu2, Guang Wu1, Licai He1, Hongzhi Li3, Haihua Gu4.   

Abstract

Scaffolding adaptor Gab2 is overexpressed in a subset of high-grade ovarian cancer. Our published work shows that Gab2 via PI3K enhances migratory behaviors and epithelial to mesenchymal transition (EMT) features of ovarian cancer cells in vitro. However, it is still unclear how Gab2/PI3K pathway reuglates EMT characteristics and whether Gab2 promotes the growth of ovarian cancer stem cell (CSC)-like population and metastatic growth. In this study, we examined the effects of Gab2 expression on CSC-like cell growth using Aldefluor and tumorshpere assays commonly used for assessing ovarian cancer cells with CSC properties. Gab2 overexpression increased the number of ALDH+ cells and tumorsphere formation in two different ovarian cancer cell lines OVCAR5 and OVCAR8, whereas knockdown of Gab2 decreased the number of ALDH+ cells and tumorsphere formation in Caov-3 cells. Furthermore, Gab2 promoted metastatic tumor growth of OVCAR5 in nude mice. Mechanistically, we uncovered that Gab2 via PI3K specifically inhibited miR-200c expression. miR-200c downregulation contributed to the Gab2-enhanced cell migratory behaviors, EMT properties, and the expansion of ALDH+ cells and tumorspheres. Furthermore, Gab2 promoted CD44 expression and cell migration/invasion through miR-200c downregulation. Our findings support a model that Gab2-PI3K pathway via miR-200c downregulation promotes CD44 expression, EMT characteristics, and CSC-like cell growth. Therapies involving miR-200c or targeting CD44 should help treat ovarian cancer with high Gab2 expression.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Gab2; Ovarian cancer; PI3K; miR-200c

Mesh:

Substances:

Year:  2019        PMID: 31194976     DOI: 10.1016/j.yexcr.2019.06.007

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

1.  GAB2 and GAB3 are expressed in a tumor stage-, grade- and histotype-dependent manner and are associated with shorter progression-free survival in ovarian cancer.

Authors:  Caglar Berkel; Ercan Cacan
Journal:  J Cell Commun Signal       Date:  2020-09-04       Impact factor: 5.782

2.  Identification of microRNA expression profiles of CD44+ ovarian cancer stem cells.

Authors:  Luyao Wang; Xiaogai Zhi; Yingying Lu; Yu Cong; Ziyi Fu; Jian Cao; Sujuan Xu; Juan Lv; Hongjie Ruan
Journal:  Arch Gynecol Obstet       Date:  2022-01-25       Impact factor: 2.493

Review 3.  Advances in Liver Cancer Stem Cell Isolation and their Characterization.

Authors:  Lu Liu; Jürgen Borlak
Journal:  Stem Cell Rev Rep       Date:  2021-01-11       Impact factor: 5.739

Review 4.  CD44 as a tumor biomarker and therapeutic target.

Authors:  Hanxiao Xu; Mengke Niu; Xun Yuan; Kongming Wu; Aiguo Liu
Journal:  Exp Hematol Oncol       Date:  2020-12-10

5.  Association of GAB2 with Quality of Life and Negative Emotions in Patients with Gastric Cancer after Postoperative Comprehensive Care.

Authors:  Juping Zhuang; Jiejie Yu; Yanchu Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-31       Impact factor: 2.650

6.  Interference of PTK6/GAB1 signaling inhibits cell proliferation, invasion, and migration of cervical cancer cells.

Authors:  Juan Li; Nan Yang; Xiaolei Tian; Linglong Ouyang; Man Jiang; Shufang Zhang
Journal:  Mol Med Rep       Date:  2022-07-27       Impact factor: 3.423

7.  USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α.

Authors:  Jiawei Cao; Du Wu; Guang Wu; Yaqi Wang; Tianhao Ren; Yang Wang; Yingshuai Lv; Wei Sun; Jieyi Wang; Changrui Qian; Licai He; Kaiyan Yang; Hongzhi Li; Haihua Gu
Journal:  Cell Death Dis       Date:  2021-06-15       Impact factor: 8.469

Review 8.  Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives.

Authors:  Ebrahim Rahmani Moghadam; Hui Li Ang; Sholeh Etehad Asnaf; Amirhossein Zabolian; Hossein Saleki; Mohammad Yavari; Hossein Esmaeili; Ali Zarrabi; Milad Ashrafizadeh; Alan Prem Kumar
Journal:  Biomolecules       Date:  2020-09-27

Review 9.  Emerging Therapeutic Agents for Colorectal Cancer.

Authors:  Marianna Nalli; Michela Puxeddu; Giuseppe La Regina; Stefano Gianni; Romano Silvestri
Journal:  Molecules       Date:  2021-12-09       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.